Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Renalytix Ai Plc LSE:RENX London Ordinary Share GB00BYWL4Y04 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -30.00 -6.67% 420.00 424.00 440.00 450.00 430.00 450.00 41,234 16:35:23
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -0.4 -1.0 - 250

RenalytixAI CEO to Speak at the 40th Annual Cowen Health Care Conference

02/03/2020 7:11pm

PR Newswire (US)


Renalytix Ai (LSE:RENX)
Historical Stock Chart


From Feb 2020 to May 2020

Click Here for more Renalytix Ai Charts.

NEW YORK, March 2, 2020 /PRNewswire/ -- Renalytix AI plc (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces it will be presenting at the Cowen 40th Annual Health Care Conference taking place on March 1-4, 2020, at the Boston Marriott Copley Place in Boston, Massachusetts.

The conference brings together top institutional investors and leading companies operating in the Health Care space. James McCullough, CEO of RenalytixAI, will be presenting on Tuesday, March 3 at 8:40am - 9:10am EST in Dartmouth, located on the 3rd floor, breakout: Exeter, 3rd floor.

The presentation will be made available on the Company's website shortly after, which can be located here: https://renalytixai.com/investors/company-presentation/. No new material or trading information will be provided.

About Kidney Disease 
Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. In the United States alone, over 40 million people are classified as having chronic kidney disease, with nearly 50 percent of individuals with advanced (Stage IV) disease unaware of the severity of their reduced kidney function. As a result, many patients progress to kidney failure in an unplanned manner, ending up having dialysis in the emergency room without ever seeing a clinical specialist, such as a nephrologist. Every day 13 patients die in the United States while waiting for a kidney transplant.

About RenalytixAI
RenalytixAI is a developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's solutions are being designed to make significant improvements in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit renalytixai.com.

Cision View original content:http://www.prnewswire.com/news-releases/renalytixai-ceo-to-speak-at-the-40th-annual-cowen-health-care-conference-301014632.html

SOURCE RenalytixAI

Copyright 2020 PR Newswire

1 Year Renalytix Ai Chart

1 Year Renalytix Ai Chart

1 Month Renalytix Ai Chart

1 Month Renalytix Ai Chart
ADVFN Advertorial
Your Recent History
LSE
RENX
Renalytix ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20200525 13:30:17